SK pharmteco has secured a multi-year manufacturing agreement with AaviGen GmbH to produce AVG-101, a lead gene therapy product designed to treat heart failure.

This collaboration is focused on advancing the development and commercialization of AVG-101, which is anticipated to be a promising treatment for patients suffering from heart failure.

Patrick Mahieux, President of Cell and Gene at SK pharmteco Europe, expressed enthusiasm about the partnership, highlighting their expertise in viral vector manufacturing and unwavering commitment to quality.

Patrick Most, CEO of AaviGen, emphasized the importance of SK pharmteco as a strategic partner in their mission to develop innovative gene therapies, commending their trustworthiness and competence.

AaviGen's therapies aim to enhance patient outcomes by concentrating on cardioprotection, contractility, and energy metabolism to restore normal cardiac function.

Utilizing heart-specific adeno-associated viral vector technology, AaviGen develops therapies that target and aim to reverse the molecular causes of heart muscle dysfunction.

As a biotechnology company, AaviGen is dedicated to creating curative gene therapies specifically for cardiovascular and cardiopulmonary diseases.